- Home
- PLBC vs YMAB Comparison
PLBC vs YMAB Comparison
Compare PLBC & YMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLBC
- YMAB
- Stock Information
- Founded
- PLBC 1980
- YMAB 2015
- Country
- PLBC United States
- YMAB United States
- Employees
- PLBC N/A
- YMAB N/A
- Industry
- PLBC Finance Companies
- YMAB Biotechnology: Pharmaceutical Preparations
- Sector
- PLBC Finance
- YMAB Health Care
- Exchange
- PLBC Nasdaq
- YMAB Nasdaq
- Market Cap
- PLBC 236.7M
- YMAB 192.4M
- IPO Year
- PLBC 2005
- YMAB 2018
- Fundamental
- Price
- PLBC $40.30
- YMAB $4.28
- Analyst Decision
- PLBC Buy
- YMAB Buy
- Analyst Count
- PLBC 4
- YMAB 10
- Target Price
- PLBC $57.00
- YMAB $17.00
- AVG Volume (30 Days)
- PLBC 16.1K
- YMAB 167.1K
- Earning Date
- PLBC 07-16-2025
- YMAB 08-15-2025
- Dividend Yield
- PLBC 3.00%
- YMAB N/A
- EPS Growth
- PLBC 1.22
- YMAB N/A
- EPS
- PLBC 4.86
- YMAB N/A
- Revenue
- PLBC $84,003,000.00
- YMAB $88,658,000.00
- Revenue This Year
- PLBC $22.16
- YMAB N/A
- Revenue Next Year
- PLBC $17.58
- YMAB $15.23
- P/E Ratio
- PLBC $8.24
- YMAB N/A
- Revenue Growth
- PLBC 6.85
- YMAB 4.92
- 52 Week Low
- PLBC $35.76
- YMAB $3.55
- 52 Week High
- PLBC $51.33
- YMAB $16.11
- Technical
- Relative Strength Index (RSI)
- PLBC 32.92
- YMAB 48.47
- Support Level
- PLBC $41.60
- YMAB $4.64
- Resistance Level
- PLBC $43.12
- YMAB $5.18
- Average True Range (ATR)
- PLBC 1.12
- YMAB 0.27
- MACD
- PLBC -0.37
- YMAB 0.02
- Stochastic Oscillator
- PLBC 0.00
- YMAB 33.67
About PLBC Plumas Bancorp
Plumas Bancorp provides various banking products and services in Northeastern California and Northwestern Nevada. It provides various deposit products such as checking, interest-bearing checking, business sweep, public funds sweep, savings, time deposit, and retirement accounts. The bank's loan portfolio consists of commercial real estate loans; commercial and industrial loans; consumer loans; agricultural loans; residential real estate loans, and construction and land development loans. The bank generates revenue from loans and investment securities in its portfolio and, to a lesser extent, service fees.
About YMAB Y-mAbs Therapeutics Inc.
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.